Cipla Emerges as Domestic Contender in Anti-Obesity Market with Yurpeak
New Delhi: India's third-largest drugmaker Cipla has made an early impact in the fast-expanding anti-obesity drug market, with its GLP-1 agonist brand Yurpeak gaining traction soon after launch, particularly across…